We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Type III Systemic Allergic Reaction to Natalizumab

Verena I. Leussink, MD; Helmar C. Lehmann, MD; Hans-Peter Hartung, MD; Ralf Gold, MD; Bernd C. Kieseier, MD
Arch Neurol. 2008;65(6):849-852. doi:10.1001/archneur.65.6.851-b.
Text Size: A A A
Published online


With interest we read the article by Krumbholz et al1 in the September 2007 issue of the Archives. Natalizumab (Biogen Idec, Cambridge, Massachusetts) is a humanized monoclonal antibody against α4 integrins, recently approved by health authorities for treating relapsing forms of multiple sclerosis.2 Infusion-related allergic reactions after the intravenous application of this drug include classical type I allergic anaphylactoid hypersensitivity reactions, typically occurring within 2 hours after infusion. The incidence of these reactions in clinical trials has been reported to be 4%.3 Krumbholz et al1 recently described a patient developing a type III hypersensitivity reaction after the second infusion of natalizumab. The clinical course of this allergic reaction appeared somewhat protracted, developing during several days; however, the overall clinical picture and the association with antinatalizumab antibodies supported the view of a delayed allergic reaction to the drug.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles